No Data
No Data
Bio-Rad Laboratories Names Roop Lakkaraju as New CFO
Evelo Biosciences Enters Into Termination and Surrender Pact With Bio-Rad
Research Alert: CFRA Retains Buy Opinion On Shares Of Bio-rad Laboratories, Inc.
We cut our target by $149 to $450, 25.4x our 2024 EPS estimate, a discount to BIO's five-year historical forward P/E average. We trim our 2023 EPS estimate by $0.46 to $15.30 and keep 2024's at $17.71.
Bio-Rad Laboratories (NYSE:BIO.B) Sees Large Volume Increase
Bio-Rad Laboratories, Inc. (NYSE:BIO.B – Get Rating) saw unusually-high trading volume on Thursday . Approximately 200 shares traded hands during trading, an increase of 2,757% from the previous sessi
Bio-Rad Laboratories (NYSE:BIO.B) Hits New 1-Year High at $464.10
Bio-Rad Laboratories, Inc. (NYSE:BIO.B – Get Rating)'s share price hit a new 52-week high during trading on Wednesday . The company traded as high as $464.10 and last traded at $464.10, with a volume
Element Biosciences and Bio-Rad Partner to Deliver Seamless RNA Sequencing Workflow Between Element's AVITI™ System and Bio-Rad's SEQuoia™ Express and SEQuoia™ Complete Stranded RNA Library Prep Kits
SAN DIEGO and HERCULES, Calif., Feb. 8, 2023 /PRNewswire/ -- Element Biosciences, Inc. — the developer of an innovative DNA sequencing platform disrupting genomics — and Bio-Rad Laboratories, Inc. (NYSE:BIO), a global
No Data